Catalyst Capital Advisors LLC Makes New $2.02 Million Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Catalyst Capital Advisors LLC acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 3rd quarter, HoldingsChannel reports. The firm acquired 112,050 shares of the company’s stock, valued at approximately $2,019,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. QRG Capital Management Inc. lifted its holdings in Teva Pharmaceutical Industries by 53.7% in the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after buying an additional 50,247 shares during the period. Capital Wealth Planning LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $2,169,000. SG Americas Securities LLC lifted its stake in shares of Teva Pharmaceutical Industries by 12.0% in the 1st quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after purchasing an additional 65,529 shares during the period. Coronation Fund Managers Ltd. purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $1,334,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Teva Pharmaceutical Industries by 38.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock valued at $21,437,000 after purchasing an additional 363,217 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TEVA shares. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. Barclays raised their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Trading Up 1.0 %

Teva Pharmaceutical Industries stock opened at $18.64 on Tuesday. The stock has a fifty day simple moving average of $18.03 and a two-hundred day simple moving average of $17.02. Teva Pharmaceutical Industries Limited has a 12 month low of $8.55 and a 12 month high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.